EUVIMEDEUVIMED entdecken
Open Access

Impact of 68 Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers

Stefan A Koerber, Manuel Röhrich, Leon Walkenbach, Jakob Liermann, Peter L Choyke, Christoph Fink, Cathrin Schroeter, Anna-Maria Spektor, Klaus Herfarth, Thomas Walle, Jeremie Calais, Hans-Ulrich Kauczor und 4 weitere

Journal of Nuclear Medicine · 2023-11 · 64 (11) · 1712-1720

DOI: 10.2967/jnumed.123.266046 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 07.09.2023. Verfasst von Stefan A Koerber und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Quinolines. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since the development of fibroblast activation protein-targeted radiopharmaceuticals, 68Ga-fibroblast activation protein inhibitor (FAPI) PET/CT has been found to be suitable for detecting primary and metastatic lesions in many types of tumors. However, there is currently a lack of reliable data regarding the clinical impact of this family of probes. To address this gap, the present study aimed to analyze the clinical impact of 68Ga-FAPI PET/CT by examining a large cohort of patients with various tumors.

Methods

In total, 226 patients (137 male and 89 female) were included in this retrospective analysis. Pancreatic cancer and head and neck cancers were the most common tumor types in this cohort. TNM stage and oncologic management were initially determined with gold standard imaging, and these results were compared with 68Ga-FAPI PET/CT. Changes were classified as major and minor.

Results

For 42% of all patients, TNM stage was changed by 68Ga-FAPI PET/CT results. Most of these changes resulted in upstaging. A change in clinical management occurred in 117 of 226 patients. Although a major change in management occurred in only 12% of patients, there was a significant improvement in the ability to accurately plan radiation therapy. In general, the highest clinical impact of 68Ga-FAPI PET/CT imaging was found in patients with lung cancer, pancreatic cancer, and head and neck tumors.

Conclusion

68Ga-FAPI PET/CT is a promising imaging probe that has a significant impact on TNM stage and clinical management. 68Ga-FAPI PET/CT promises to be a crucial new technology that will improve on conventional radiologic imaging methods such as contrast-enhanced CT and contrast-enhanced MRI typically acquired for cancer staging.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsQuinolinesHumansFemaleMaleGallium RadioisotopesPositron Emission Tomography Computed TomographyRetrospective StudiesMedical OncologyFluorodeoxyglucose F18

Stichwörter der Autor:innen

FAPIPET/CTmanagementradiation therapystaging

Substanzen

Gallium RadioisotopesFluorodeoxyglucose F18Quinolines

Autor:innen und Institutionen

  • Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
  • National Center of Radiation Oncology, Heidelberg Institute of Radiation Oncology, Heidelberg, Germany.
  • Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany.
  • Department of Radiation Oncology, Barmherzige Brueder Hospital Regensburg, Regensburg, Germany.
  • Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany; manuel.roehrich@med.uni-heidelberg.de.
  • Department of Nuclear Medicine, Mainz University Hospital, Mainz, Germany.

Zitieren

APA

Koerber, S. A., Röhrich, M., Walkenbach, L., Liermann, J., Choyke, P. L., Fink, C., Schroeter, C., Spektor, A. M., Herfarth, K., Walle, T., Calais, J., Kauczor, H. U., Jaeger, D., Debus, J., Haberkorn, U., & Giesel, F. L. (2023). Impact of 68 Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers. Journal of Nuclear Medicine, 64(11), 1712-1720. https://doi.org/10.2967/jnumed.123.266046

Vancouver

Koerber SA, Röhrich M, Walkenbach L, Liermann J, Choyke PL, Fink C, et al. Impact of 68 Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers. Journal of Nuclear Medicine. 2023;64(11):1712-1720. doi:10.2967/jnumed.123.266046

BibTeX
@article{Koerber2023,
  author = {Koerber, Stefan A and Röhrich, Manuel and Walkenbach, Leon and Liermann, Jakob and Choyke, Peter L and Fink, Christoph and Schroeter, Cathrin and Spektor, Anna-Maria and Herfarth, Klaus and Walle, Thomas and Calais, Jeremie and Kauczor, Hans-Ulrich and Jaeger, Dirk and Debus, Juergen and Haberkorn, Uwe and Giesel, Frederik L},
  title = {Impact of 68 Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  volume = {64},
  number = {11},
  pages = {1712--1720},
  doi = {10.2967/jnumed.123.266046}
}
Kostenlos starten →